- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Milestone continues the progress towards detection of all 20 amino acids by end of 2026 BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids […] The post Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™ appeared first on Quantum-Si.
Growing Multi-City Program Continues to Increase Awareness of Proteus and Support Customer Funnel Development Ahead of Commercial Launch BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate market […] The post Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities appeared first on Quantum-Si.
BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C. Wainwright 28th Annual Global Investment Conference taking place at the Lotte New York Palace Hotel, September 14-16, […] The post Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference appeared first on Quantum-Si.
Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing BRANFORD, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule […] The post Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update appeared first on Quantum-Si.
BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the second quarter 2026 on Thursday, August 13, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief […] The post Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026 appeared first on Quantum-Si.
BRANFORD, Conn.–(BUSINESS WIRE)–Jun. 16, 2026– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 134,141 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity […] The post Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) appeared first on Quantum-Si.
BRANFORD, Conn.–(BUSINESS WIRE)–Jun. 10, 2026– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced a partnership with Cell Signaling Technology (“CST”) to advance and validate next-generation protein sequencing and analysis of post-translational modifications (“PTM”) on the Proteus™ single-molecule protein sequencing platform. The partnership […] The post Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™ appeared first on Quantum-Si.
ASMS 2026 Poster – Identification of hemoglobin (Hb) variants is of significant value in the clinical diagnosis of hemoglobinopathies. Conventional methods used to identify Hb variants in clinical laboratories can narrow down the range of candidates for a Hb variant sample but are unable to pinpoint the exact Hb variant. In this study, a semiconductor […] The post Exploration of semiconductor chip-based single-molecule protein sequencing for identification of hemoglobin variants appeared first on Quantum-Si.
ASMS 2026 Poster – Post-translational modifications (PTMs) are critical regulators of protein function and are extremely diverse in both types and frequencies1 While many PTMs can be readily identified, identification and site localization can still be challenging when the PTM introduces small mass changes or when multiple modification sites are possible Here, we demonstrate how N-terminal amino acid (NAA) recognizer-based sequencing, an emerging single-molecule […] The post High-resolution detection of post-translational modifications using single-molecule protein sequencing appeared first on Quantum-Si.
Multi-City Roadshow is Driving Awareness of Proteus and Developing Customer Funnel for Commercial Launch BRANFORD, Conn.–(BUSINESS WIRE)–Jun. 3, 2026– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate the education of the market on […] The post Quantum-Si Announces the Expansion of the Proteus™ Roadshow appeared first on Quantum-Si.
